RNXT

RenovoRx, Inc.

2.38 USD

Last updated Sep 4, 20:11 UTC

Yesterday HIGH

$2.52

Yesterday LOW

$1.98

52w HIGH

$2.59

52w LOW

$0.7

EPS

-0.05

PE

-47.60

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

RenovoRx, Inc. stock is up 124.53% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Mon Jun 1, 2026

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.
Benzinga Newsdesk

Thu May 28, 2026

RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer

The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used
Benzinga Newsdesk

Tue May 26, 2026

RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common
Benzinga Insights

Thu May 14, 2026

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga Newsdesk

Thu May 14, 2026

RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.

RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
Benzinga Newsdesk

Thu May 14, 2026

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The
Benzinga Insights

Thu May 14, 2026

Earnings Scheduled For May 14, 2026
Benzinga Newsdesk

Thu Apr 9, 2026

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13 to $13.5.
Benzinga Newsdesk

Wed Apr 8, 2026

HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a Buy and maintains $3 price target.
Benzinga Newsdesk

Wed Apr 8, 2026

RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum"

The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted localization and